AAV CMV-dSaCas9-KRAB-bGHpA Citations (3)
Originally described in: RNA-guided transcriptional silencing in vivo with S. aureus CRISPR-Cas9 repressors.Thakore PI, Kwon JB, Nelson CE, Rouse DC, Gemberling MP, Oliver ML, Gersbach CA Nat Commun. 2018 Apr 26;9(1):1674. doi: 10.1038/s41467-018-04048-4. PubMed Journal
Articles Citing AAV CMV-dSaCas9-KRAB-bGHpA
| Articles |
|---|
| Unexpected Mutations by CRISPR-Cas9 CTG Repeat Excision in Myotonic Dystrophy and Use of CRISPR Interference as an Alternative Approach. Ikeda M, Taniguchi-Ikeda M, Kato T, Shinkai Y, Tanaka S, Hagiwara H, Sasaki N, Masaki T, Matsumura K, Sonoo M, Kurahashi H, Saito F. Mol Ther Methods Clin Dev. 2020 May 22;18:131-144. doi: 10.1016/j.omtm.2020.05.024. eCollection 2020 Sep 11. PubMed |
The PROTECTOR strategy employs dCas orthologs to sterically shield off-target sites from CRISPR/Cas activity.
Sapozhnikov DM, Szyf M.
Sci Rep. 2023 Feb 9;13(1):2280. doi: 10.1038/s41598-023-29332-2.
PubMed
Associated Plasmids |
| Molecular basis of FAAH-OUT-associated human pain insensitivity. Mikaeili H, Habib AM, Yeung CW, Santana-Varela S, Luiz AP, Panteleeva K, Zuberi S, Athanasiou-Fragkouli A, Houlden H, Wood JN, Okorokov AL, Cox JJ. Brain. 2023 Sep 1;146(9):3851-3865. doi: 10.1093/brain/awad098. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.